Efficacy and Safety of Polatuzumab Vedotin Combined with Chemotherapy in the Treatment of Relapsed and Refractory Diffuse Large B-Cell Lymphoma
10.19746/j.cnki.issn1009-2137.2025.06.010
- VernacularTitle:维泊妥珠单抗联合化疗治疗复发难治弥漫大B细胞淋巴瘤的疗效及安全性
- Author:
Ke-Ting JIN
1
;
Jin-Dan XIA
;
Chu-Yun QIAN
;
Qian ZHANG
;
Qian JIANG
;
Song-Di CHEN
;
Wei-Ze ZHANG
;
Lu-Ling MAO
;
Yi ZHAO
Author Information
1. 浙江大学医学院附属第一医院良渚分院血液内科,浙江 杭州 311113
- Publication Type:Journal Article
- Keywords:
diffuse large B-cell lymphoma;
relapsed and refractory;
polatuzumab vedotin
- From:
Journal of Experimental Hematology
2025;33(6):1617-1622
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the efficacy and safety of polatuzumab vedotin(pola)combined with chemotherapy in the treatment of relapsed and refractory diffuse large B-cell lymphoma(R/R DLBCL).Methods:A total of 23 patients with R/R DLBCL treated at the First Affiliated Hospital of Zhejiang University and its Liangzhu Branch from April 2023 to March 2024 were retrospectively collected.All patients were treated with pola combined with chemotherapy regimens such as BR,R-GDP,R-CHOP,or other regimens.Results:All 23 patients were evaluable for efficacy,with 10 achieving complete response(CR),7 partial response(PR),3 stable disease(SD),and 3 progressive disease(PD).The most common adverse events included myelosuppression,fever,and pulmonary infection.No severe adverse events resulted in drug withdrawal.Conclusion:Pola combined with chemotherapy demonstrates promising efficacy and a favorable safety profile in the treatment of R/R DLBCL.
